LETTER
Preparation of 2-Isoxazolines from O-Propargylic Hydroxylamines
465
Org. Lett. 2004, 6, 2485. (d) Xu, W.-M.; Wang, Y.-G.;
mmol, 74%). IR: nmax = 3066 (w), 2954 (m), 2887 (m), 1584
(m), 1476 (m), 1434 (s), 1342 (s), 1037 (m), 934 (m), 880 (s),
643 (m) cm–1. 1H NMR (300 MHz, CDCl3): d = 3.48 (2 H, t,
J = 8.7 Hz, C4-H2), 4.51 (2 H, t, J = 8.7 Hz, C5-H2), 7.26–
7.38 (2 H, m, Ph), 7.43 (1 H, dd, J = 0.7, 6.3 Hz, Ph), 7.64 (1
H, dd, J = 0.8, 7.9 Hz, Ph). MS (EI): m/z (%) 183 (33) [M+],
181 (100) [M+], 155 (20), 153 (79), 151 (87), 137 (65), 113
(20), 111 (53), 75 (74). Anal. Calcd for C9H8ClNO: C, 59.52;
H, 4.44; N, 7.71. Found: C, 59.60; H, 4.46; N, 7.79%.
Compounds 12, 13,13 14, 15,14 16, 1713 and 1815 were
prepared using an analogous procedure.
Miao, M.-Z.; Huang, X. Synthesis 2005, 2143. (e) Fedou,
N. M.; Parsons, P. J.; Viseux, E. M. E.; Whittle, A. J. Org.
Lett. 2005, 7, 3179; and references therein.
(6) (a) Albini, F.; Vitali, D.; Oberti, R.; Caramella, P. J. Chem.
Res., Synop. 1980, 348. (b) Curran, D. P.; Scanga, S. A.;
Fenk, C. J. J. Org. Chem. 1984, 49, 3474. (c) Kurth, M. J.;
Rodriguez, M. J.; Olmstead, M. M. J. Org. Chem. 1990, 55,
283. (d) Baranski, A.; Banki, G. Collect. Czech. Chem.
Commun. 1991, 56, 425. (e) Rai, K. M. L.; Hassner, A.
Indian J. Chem., Sect. B.: Org. Chem. Incl. Med. Chem.
1997, 36, 242. (f) Basel, Y.; Hassner, A. Synthesis 1997,
309. (g) Maugein, N.; Wagner, A.; Mioskowski, C.
Tetrahedron Lett. 1997, 38, 1547. (h) Enders, D.; Haertwig,
A.; Ransink, J. Eur. J. Org. Chem. 1998, 1793. (i) Maiti,
D.; Bhattacharya, P. K. Synlett 1998, 385. (j) Sampath
Kumar, H. M.; Anjaneyula, S.; Yadav, J. S. Synth. Commun.
1999, 29, 877. (k) Fenk, C. J. Tetrahedron Lett. 1999, 40,
7955. (l) Pirrung, M. C.; Tumey, L. N.; Raetz, C. R. H.;
Jackman, J. E.; Snehalatha, K.; McClerren, A. L.; Fierke, C.
A.; Gantt, S. L.; Rusche, K. M. J. Med. Chem. 2002, 45,
4359.
Preparation of 5-Phenyl-2-isoxazoline (19).
The O-propargylic hydroxylamine hydrochloride salt 9
(1.84 g, 10.0 mmol) was dissolved in CH2Cl2 (20 mL) and
washed with sat. NaHCO3 solution (20 mL). The aqueous
phase was extracted with CH2Cl2 (3 × 10 mL) and the
combined extracts were dried over MgSO4 and concentrated
in vacuo at 40 °C to give the free hydroxylamine (1.44 g, 9.8
mmol). A portion of this material (300 mg, 2.04 mmol) was
dissolved in dry MeOH (5 mL) and heated at reflux under a
nitrogen atmosphere for 8 h. The solution was then
concentrated in vacuo at 40 °C and the crude product
purified by flash chromatography (gradient elution; EtOAc–
heptane) to give the isoxazoline 19 as an oil (188 mg, 1.28
mmol, 63%). IR and 1H NMR spectra as previously
reported.16 Compound 20 was prepared using an analogous
procedure.
Preparation of 3-(4-Chlorophenyl)-2-isoxazoline (13).
Methyl hydrazine (0.15 g, 3.3 mmol) was instilled into a
cooled solution (0 °C) of the phthalimide (25) (1.00 g, 3.2
mmol) in CH2Cl2 (10 mL) under a nitrogen atmosphere. The
mixture was stirred at r.t. for 19 h, after which time the
precipitated 2-methyl-2,3-dihydrophthalazine-1,4-dione
was removed by filtration and discarded. The filtrate was
diluted with Et2O (50 mL), cooled to 0 °C and anhyd HCl(g)
was bubbled through for approximately 5 min to give a small
amount of brown precipitate which was filtered off and
discarded. The filtrate was then concentrated in vacuo at
40 °C and the crude product purified by flash
(7) (a) Kim, Y. H.; Kim, S. H.; Park, D. H. Tetrahedron Lett.
1993, 34, 6063. (b) Pearce, A. J.; Walter, D. S.; Frampton,
C. S.; Gallagher, T. J. Chem. Soc., Perkin Trans. 1 1998,
847. (c) Basappa Sadashiva, M. P.; Mantelingu, K.;
Nanjunda Swamy, S.; Rangappa, K. S. Bioorg. Med. Chem.
2003, 11, 4539.
(8) Rodriguez-Franco, M. I.; Dorronsoro, I.; Martinez, A.
Synthesis 2001, 1711.
(9) (a) Tecle, H.; Lauffer, D. J.; Mirzadegan, T.; Moos, W. H.;
Moreland, D. W.; Pavia, M. R.; Schwarz, R. D.; Davis, R. E.
Life Sci. 1993, 52, 505. (b) Tecle, H.; Barrett, S. D.; Lauffer,
D. J.; Augelli-Szafran, C.; Brann, M. R.; Callahan, M. J.;
Caprathe, B. W.; Davis, R. E.; Doyle, P. D.; Eubanks, D.;
Lipiniski, W.; Mirzadegan, T.; Moos, W. H.; Moreland, D.
W.; Nelson, C. B.; Pavia, M. R.; Raby, C.; Schwarz, R. D.;
Spencer, C. J.; Thomas, A. J.; Jaen, J. C. J. Med. Chem.
1998, 41, 2524.
(10) Benting, J.; Leonhardt, M.; Lindell, S. D.; Tiebes, T. Comb.
Chem. High Throughput Screening 2005, 8, 649.
(11) Preparation of 3-(2-Chlorophenyl)-2-isoxazoline (11).
A mixture of the O-propargylic hydroxylamine
chromatography (gradient elution; EtOAc–heptane) to give
the isoxazole 13 as a crystalline solid (380 mg, 2.1 mmol,
65%); mp 114–116 °C (lit.13 116–117 °C). IR and 1H NMR
spectra as previously reported.13
hydrochloride salt 1 (275 mg, 1.26 mmol), K2CO3 (175 mg,
1.27 mmol) and dry MeOH (5 mL) was heated at reflux
under a nitrogen atmosphere for 7.5 h. The solution was then
concentrated in vacuo at 40 °C, H2O (5 mL) was added and
the mixture was extracted with CH2Cl2 (3 × 10 mL). The
combined organic extracts were dried with MgSO4 and
concentrated in vacuo at 40 °C. The crude product was
purified by flash chromatography (gradient elution; EtOAc–
heptane) to give the isoxazoline 11 as an oil (169 mg, 0.93
Compounds 17–20 were isolated as racemic mixtures.
(12) Davies, S. G.; Jones, S.; Sanz, M. A.; Teixeira, F. C.; Fox, J.
F. J. Chem. Soc., Chem. Commun. 1998, 2235.
(13) Kumagai, T.; Shimizu, K.; Kawamura, Y.; Mukai, T.
Tetrahedron 1981, 37, 3365.
(14) Maire, M. Bull. Soc. Chim. Fr. 1908, 3, 272.
(15) D’Alcontres, G. S. Gazz. Chim. Ital. 1952, 82, 627.
(16) Huisgen, R.; Christl, M. Chem. Ber. 1973, 106, 3291.
Synlett 2006, No. 3, 463–465 © Thieme Stuttgart · New York